Samsung Group Set To Enter Biosimilars Market With $1.9 Billion Investment
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Samsung Group has ended years of exploration for new business realms beyond its traditional pipeline of semiconductors and electronics products; South Korea's leading conglomerate is set to enter the healthcare sector, particularly biosimilars and medical devices, with an initial investment of roughly $4.1 billion
You may also be interested in...
Korea’s CJ CheilJedang Corp. Under Police Investigation For Rebates
Probes into CJ and Dong-A signal Korea’s anti-rebate stance won’t stop anytime soon.
Samsung Looks To Mirror Fellow Korean Pharma Celltrion's Path From CMO To Biosimilars Developer With Quintiles JV
Samsung plans to begin construction on its manufacturing plant in Incheon during the first half of this year, and production is expected to commence in the first half of 2013.
Samsung Looks To Mirror Fellow Korean Pharma Celltrion's Path From CMO To Biosimilars Developer With Quintiles JV
Samsung plans to begin construction on its manufacturing plant in Incheon during the first half of this year, and production is expected to commence in the first half of 2013.